Similar articles

• The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia.

  Mayer RJ, Weinstein HJ, Coral FS, Rosenthal DS, Frei E 3rd. Mayer RJ, et al. Cancer Treat Rep. 1982 Jul;66(7):1455-62. Cancer Treat Rep. 1982. PMID: 7046925 No abstract available.
• [Prediction of the response to chemotherapy in acute leukemia through in-vitro incorporation of tritiated thymidine].

  Zittoun R, Bouchard M, Facquet-Danis J, Percie-Du-Sert M, Bousser J. Zittoun R, et al. Ann Med Interne (Paris). 1974 Nov;125(11):811-6. Ann Med Interne (Paris). 1974. PMID: 4618066 Clinical Trial. French. No abstract available.
• The therapy of acute myelogenous leukemia, a major challenge of onco-hematology.

  Boiron M. Boiron M. Pathol Biol (Paris). 1986 Mar;34(3):153-6. Pathol Biol (Paris). 1986. PMID: 3517783 No abstract available.
• Chemotherapy of acute myelogenous leukaemia.

  Marie JP, Zittoun R. Marie JP, et al. Baillieres Clin Haematol. 1991 Jan;4(1):97-113. doi: 10.1016/s0950-3536(05)80286-0. Baillieres Clin Haematol. 1991. PMID: 2039863 Review. No abstract available.
• Fludarabine for treatment of adult acute myelogenous leukemia.

  Gandhi V. Gandhi V. Leuk Lymphoma. 1993;11 Suppl 2:7-13. doi: 10.3109/10428199309064255. Leuk Lymphoma. 1993. PMID: 8124234 Review.